Update shared on 15 Nov 2025
Fair value Decreased 11%Analysts have increased their price target for Beauty Health from $2.00 to $2.50. They cite improved device sales management, innovation in consumables, and deeper provider engagement as drivers for this positive outlook.
Analyst Commentary
Following the recent price target revision, analysts have provided a nuanced assessment of Beauty Health's prospects. Their commentary highlights both positive drivers and ongoing risks for the company.
Bullish Takeaways
- Bullish analysts point to improved management of device sales churn. This is expected to stabilize revenues and provide a foundation for future growth.
- Innovation in consumables is viewed as a key catalyst, enhancing recurring revenue streams and supporting higher valuation multiples.
- Deeper engagement with providers in the 35,000-unit installed base is believed to foster increased product adoption and strengthen customer loyalty.
- The CEO's recent strategic reset is seen as effectively addressing prior execution challenges. This has increased confidence in the company’s operational direction.
Bearish Takeaways
- Bearish analysts caution that, despite the improvements, device sales churn remains a notable risk and could weigh on near-term growth.
- There are concerns about the pace and sustainability of consumables innovation, particularly in maintaining competitive differentiation.
- Some remain cautious about broader execution risks as management implements further changes across the business.
- Ongoing hold ratings suggest that upside may be limited until more consistent growth and profitability are demonstrated.
What's in the News
- The Beauty Health Company released guidance for 2025, forecasting net sales between $293 million and $300 million. (Company Guidance)
- Pedro Malha has been appointed Chief Executive Officer, effective October 1, 2025. He will succeed Marla Beck, who will transition to an advisory role. (Executive Announcement)
- Marla Beck, the outgoing CEO, is recognized for steering Beauty Health through operational and strategic transformation. Her tenure included innovation pipeline development and profitability improvements. (Executive Transition)
Valuation Changes
- Fair Value Estimate: Decreased from $2.17 to $1.93, reflecting a more conservative assessment of intrinsic value.
- Discount Rate: Increased from 10.69% to 12.24%, which indicates higher perceived risk in future cash flows.
- Revenue Growth: Upgraded from 3.23% to 4.01%, pointing to stronger expected top-line performance.
- Net Profit Margin: Marginally improved from 5.18% to 5.21%, suggesting slight gains in profitability expectations.
- Future P/E Ratio: Lowered from 22.43x to 21.31x, which signals subdued long-term growth or investor sentiment.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.